Capillary Malformation-Arteriovenous Malformation (CM-AVM)

Welcome to the Noonan Syndrome Road Map

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

FDA Approves Radicava (edaravone) to Treat ALS

Regenerative Neurobiology

ALS Treatment Updates

  • ALS walk to be held next weekend at Cosmo-Bethel Park 17 Aug 2017 23:39 Columbia Missourian COLUMBIA — The annual Columbia ALS walk is something "you can wrap your heart around," Bill Byington said. In 2014, after what Byington described as "a very private, hard battle," his father died of ALS, also known as Lou Gehrig's …
  • Quad Cities Walk to Defeat ALS Brings Hope to Iowans with ALS 17 Aug 2017 19:58 River Cities Reader The ALS Association Celebrates Supporters in the Quad Cities Thanks to generous support for the ALS Association, the first ALS treatment drug in 22 years was approved this past May. While the search continues for more treatments and cure, community …
  • GHS Neurological Institute recognized by ALS Association 12 Aug 2017 01:13 WYFF GHS Neurological Institute recognized by ALS Association Copy Link Copy {copyShortcut} to copy Link copied! Updated: 8:30 PM EDT Aug 11, 2017 Hide Transcript Show Transcript WEBVTT BRENNAN: GHS IS NOW THE ONLYHOSPITAL IN SOUTH CAROLINARECOGNIZED BY THE …
  • Two ALS patients in Buffalo first in U.S. to receive new drug 11 Aug 2017 19:24 United Press International (UPI) Aug. 11 (UPI) -- Two patients at the DENT Neurologic Institute near Buffalo, N.Y., will be the first in the nation to receive the newest drug to treat ALS in more than 20 years. Amyotrophic lateral sclerosis, or ALS, is a progressive degenerative disease …
  • Amyotrophic Lateral Sclerosis (ALS) Treatment Market Is Expected To Reach US$ 306.6 Mn By 2025 10 Aug 2017 14:57 PR Log New Market Research Reports Title "Amyotrophic Lateral Sclerosis (ALS) Treatment Market Is Expected To Reach US$ 306.6 Mn By 2025 – Credence Research" Has Been Added to Credenceresearch.com Report Database.     SAN JOSE, Calif. - Aug. 10, 2017 - …
  • Nancy Frates Says New ALS Treatment Offers Hope 09 Aug 2017 03:29 CBS Boston BOSTON (CBS) – A powerful wave of hope moving through the ALS community – the FDA has approved a drug for the first time in more than two decades that slows the symptoms of the devastating disease. Radicava has shown promising signs in Japan – slowing the …
  • First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S. 08 Aug 2017 15:07 salesandmarketingnetwork.com JERSEY CITY, N.J., Aug. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral …
  • U.S. STOCKS ON THE MOVE- Barnes & Noble, Freeport-McMoRan, Interpublic 25 Jul 2017 19:04 The Times of India * Eikon search string for individual stock moves: STXBZ * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P hit a record and the Dow was higher on Tuesday, …
  • Wins $15.9M CIRM Grant for Phase III Trial of ALS Cell Therapy 22 Jul 2017 10:40 4-traders BrainStorm Cell Therapeutics has won a $15.9 million grant from Californias regenerative medicine agency toward a Phase III trial of its amyotrophic lateral sclerosis (ALS) cell therapy candidate NurOwn. The governing board of the California Institute for …
  • BrainStorm Wins $15.9M CIRM Grant for Phase III Trial of ALS Cell Therapy 21 Jul 2017 15:22 Genetic Engineering News BrainStorm said the patient population will be optimized to include faster-progressing patients who showed superior outcomes in NurOwn’s Phase II ALS trial (NCT02017912).  The company reported positive topline results from that 48-patient trial in July …

 

Showing listings 1-9 of 4323

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

ALS Groups

 

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

Featured

View all

Noonan Syndrome News

  • At ages 9 and 11, boys are veteran health lobbyists 22 Aug 2017 08:41 Philly HANOVER, Pa. - Ask 11-year-old Jackson Corbin and 9-year-old Henry Corbin of Hanover why they are lobbying senators in Capitol Hill every week and they say, "We have to save our health care." The brothers have spent time in Washington and …
  • Children lobbying for health care 19 Aug 2017 07:23 The Fresno Bee Ask 11-year-old Jackson Corbin and 9-year-old Henry Corbin of Hanover why they are lobbying senators in Capitol Hill every week and they say, "We have to save our health care." The brothers have spent time in D.C. and Harrisburg reaching out to …
  • As GOP health bill collapses, state Medicaid backers worry 19 Jul 2017 03:56 Pocono Record Online Wes Venteicher, The Pittsburgh Tribune-Review (TNS) Consumer health advocates remained wary Tuesday of potential changes to Medicaid even as a Senate Republican proposal to reduce funding for the program sank from a lack of support. “We know that this is …
  • As GOP health bill collapses, worries remain among Pennsylvania Medicaid backers 18 Jul 2017 21:54 Pittsburgh Tribune-Review Updated 9 minutes ago Consumer health advocates remained wary Tuesday of potential changes to Medicaid even as a Senate Republican proposal to reduce funding for the program sank from a lack of support. “We know that this is not a final victory,” said …
  • Board of Trustees of the Leland Stanford Junior University v. Chinese University of Hong Kong (Fed. Cir. 2017) 05 Jul 2017 04:49 Patent Docs By Kevin E. Noonan -- Detection of paternal cell-free fetal DNA (cffDNA) in maternal blood (the technology at issue in Ariosa v. Sequenom) was in a different incarnation the subject of an interference between professors at two universities; the decision …
  • Can this Nation Remain United? 21 Jun 2017 13:24 Jewish Press Watching the level of social and political discourse in the USA (and for that matter around the world) descend into deeper and deeper levels of hostility, I want to see if I can contribute something useful. The horror this week in Alexandria VA, as an …
  • New On-Demand Targeted Next-Generation Sequencing Panels for Inherited Disease Research Deliver User Customization Without High Upfront Cost 24 May 2017 06:59 Kait Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please …
  • The fragile life of 15-month-old Isabella Hope Dowd 19 May 2017 00:32 Stuff CAITLIN MOORBY Last updated 11:11, May 19 2017 CHRISTINE CORNEGE/ FAIRFAX NZ "We just have hope that she will pull through, but we don't want her to be in any pain." Lives don't get much harder than baby Isabella's. She has spent …
  • Natera, Inc. Announces Launch of Vistara Single-Gene Mutation NIPT 08 May 2017 14:08 KTEN Online Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please …
  • ‘Totally surreal experience’: Edmonton woman with rare disorder runs Boston Marathon. 25 Apr 2017 02:49 CIHF Shawne Flaherty has just returned from accomplishing the greatest thrill of her life – running the 2017 Boston Marathon. The thrill is even greater for this 48-year-old- since she suffers from a rare condition and wasn’t expected to live past her teens. “ …

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

[google_news query=’als’ topic=snc topic=t topic=b topic=s topic=m]

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2017 My City Med. All Rights Reserved.

or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Skip to toolbar